Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2002 Jun 1;324(7349):1287-8.
doi: 10.1136/bmj.324.7349.1287.

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Peter Jüni, Anne W S Rutjes, Paul A Dieppe
Editorial

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Peter Jüni et al. BMJ. .

Erratum in

  • BMJ 2002 Jun 29;324(7353):1538
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Main results according to published report (top) and pre-specified protocol (bottom). Alternate definition of ulcer related complications, pre-specified by the FDA, included more stringent criteria to address serious gastrointestinal bleeding. P values are from log rank tests.
Figure 2
Figure 2
Kaplan-Meier estimates for ulcer complications according to traditional definition. Results are truncated after 12 months, no ulcer complications occurred after this period. Adapted from Lu 2001.
See this image and copyright information in PMC

Comment in

References

    1. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo- oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96:7563–7568. - PMC - PubMed
    1. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247–1255. - PubMed
    1. Okie S. Missing data on Celebrex. Full study altered picture of drug. Washington Post 2001;5 Aug:A11.
    1. Berg Hrachovec J, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001;286:2398. - PubMed
    1. Wright JM, Perry TL, Bassett KL, Chambers KG. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001;286:2398–2399. - PubMed

Publication types

MeSH terms